| P50 | author | Theodore Oliphant | Q81871283 |
| P2093 | author name string | Simon Bergqvist | |
| | Regis Doyonnas | |
| | Amy C Shen | |
| | Paul D Lira | |
| | Timothy S Fisher | |
| | Sharon A Sokolowski | |
| | Sangita M Baxi | |
| | Cris Kamperschroer | |
| | Chunli Huang | |
| | Leslie L Sharp | |
| | Allison Rohner | |
| | Victoria A Love | |
| P2860 | cites work | Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia | Q24594920 |
| | T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia | Q24632975 |
| | Immune Modulation through 4-1BB Enhances SIV Vaccine Protection in Non-Human Primates against SIVmac251 Challenge | Q28740359 |
| | CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans | Q29614348 |
| | Cytokine-mediated disruption of lymphocyte trafficking, hemopoiesis, and induction of lymphopenia, anemia, and thrombocytopenia in anti-CD137-treated mice | Q33374623 |
| | A novel form of 4-1BBL has better immunomodulatory activity than an agonistic anti-4-1BB Ab without Ab-associated severe toxicity | Q33586493 |
| | In vivo persistence, tumor localization, and antitumor activity of CAR-engineered T cells is enhanced by costimulatory signaling through CD137 (4-1BB) | Q34073529 |
| | Humanized mice in translational biomedical research | Q34607151 |
| | Immune modulation with weekly dosing of an agonist CD40 antibody in a phase I study of patients with advanced solid tumors | Q34616576 |
| | A new Hu-PBL model for the study of human islet alloreactivity based on NOD-scid mice bearing a targeted mutation in the IL-2 receptor gamma chain gene. | Q34728143 |
| | The promise and potential pitfalls of chimeric antigen receptors | Q34970378 |
| | CD137 stimulation delivers an antigen-independent growth signal for T lymphocytes with memory phenotype | Q35828831 |
| | Defining the critical hurdles in cancer immunotherapy | Q35916968 |
| | Genes that distinguish physiological and pathological angiogenesis | Q36087324 |
| | Multivalent 4-1BB binding aptamers costimulate CD8+ T cells and inhibit tumor growth in mice. | Q36183600 |
| | Dual immunoregulatory pathways of 4-1BB signaling | Q36573413 |
| | Three is better than one: pre-ligand receptor assembly in the regulation of TNF receptor signaling | Q36797904 |
| | The promise of 4-1BB (CD137)-mediated immunomodulation and the immunotherapy of cancer | Q37118182 |
| | Twelve immunotherapy drugs that could cure cancers | Q37118201 |
| | The role of TNF superfamily members in T-cell function and diseases | Q37332068 |
| | Activation of human B cells by the agonist CD40 antibody CP-870,893 and augmentation with simultaneous toll-like receptor 9 stimulation | Q37422374 |
| | Immune regulation by 4-1BB and 4-1BBL: complexities and challenges | Q37474935 |
| | Immunobiology of cancer therapies targeting CD137 and B7-H1/PD-1 cosignal pathways | Q37768063 |
| | Clinical Experiences With Anti-CD137 and Anti-PD1 Therapeutic Antibodies | Q37809159 |
| | Cancer immunotherapy – revisited | Q37908998 |
| | Inhibitory Fcγ Receptor Engagement Drives Adjuvant and Anti-Tumor Activities of Agonistic CD40 Antibodies | Q38275268 |
| | Agonist anti-CD137 mAb act on tumor endothelial cells to enhance recruitment of activated T lymphocytes. | Q39602916 |
| | Intratumoral injection of interferon-α and systemic delivery of agonist anti-CD137 monoclonal antibodies synergize for immunotherapy. | Q39724400 |
| | ERK-dependent Bim modulation downstream of the 4-1BB-TRAF1 signaling axis is a critical mediator of CD8 T cell survival in vivo | Q39975642 |
| | Activation of resting human primary T cells with chimeric receptors: costimulation from CD28, inducible costimulator, CD134, and CD137 in series with signals from the TCR zeta chain | Q40605275 |
| | Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo | Q42938990 |
| | Cloning, expression and characterization of monkey (Macaca fascicularis) CD137. | Q44965339 |
| | Development and Homeostasis of T Cell Memory in Rhesus Macaque | Q45882091 |
| | 4-1BB and OX40 act independently to facilitate robust CD8 and CD4 recall responses | Q51996548 |
| | Interaction with FcγRIIB is critical for the agonistic activity of anti-CD40 monoclonal antibody | Q53234389 |
| | Serum levels of sCD137 (4-1BB) ligand are prognostic factors for progression in acute myeloid leukemia but not in non-Hodgkin's lymphoma | Q53344642 |
| | Ipilimumab. | Q55054369 |
| | Levels of soluble CD137 are enhanced in sera of leukemia and lymphoma patients and are strongly associated with chronic lymphocytic leukemia | Q58043051 |
| P433 | issue | 10 | |
| P921 | main subject | antibody | Q79460 |
| | monoclonal antibody | Q422248 |
| | cell function | Q95674809 |
| P304 | page(s) | 1721-1733 | |
| P577 | publication date | 2012-03-11 | |
| P1433 | published in | Cancer Immunology, Immunotherapy | Q5031409 |
| P1476 | title | Targeting of 4-1BB by monoclonal antibody PF-05082566 enhances T-cell function and promotes anti-tumor activity | |
| P478 | volume | 61 | |